ALP Bio adds €161K Venture Kick grant weeks after $2.2M pre-seed
What's the deal? Swiss biotech startup ALP BioDealroom has a profile for this one. Try Dealroom → has secured a US$137.5K (€161,000) grant from Venture KickDealroom has a profile for this one. Try Dealroom → to fund the commercial development of its platform, which helps drug developers spot immune-related risks earlier in the process. The company combines human immune tissue models with AI to improve the safety and success rate of biologic medicines.
Why now? The grant follows ALP Bio's $2.2 million pre-seed round led by 42CAPDealroom has a profile for this one. Try Dealroom → in late April 2026, a quick re-raise that adds institutional backing within Switzerland's innovation ecosystem.
What's the endgame? Biologic drugs, including many therapeutic antibodies, can trigger unwanted immune responses that reduce effectiveness and drive up clinical failure rates. ALP Bio's platform pairs human tonsil-derived immune models with AI-based protein modelling to predict how the immune system reacts to therapeutic antibodies, letting researchers mitigate those risks before trials.
The company was founded by Christian Vahlensiek (chief executive officer), Lucas Schaus (chief scientific officer), Anatol Ehrlich (chief technology officer), and Punit Mehra (chief business officer), combining expertise in immunology, AI, protein engineering, and business development.
Where the money goes: The Venture Kick funding will co-finance ALP Bio's first pilot projects with pharmaceutical partners, helping the startup validate its technology in real-world settings and strengthen its commercial position.
The signal: Venture Kick's three-stage model can channel up to US$137.5K to early-stage Swiss startups before they tap larger equity rounds, and it has backed over 1,100 projects since 2007. ALP Bio's quick re-raise reflects growing investor interest in platforms that combine human-relevant biology and AI to de-risk biologic development, where late-stage safety surprises remain costly.
Read more: Tech.eu
Image credit: Generated with Gemini
